The 3 Most Important Things to Remember When Sharing Documents During Due Diligence

Posted by ShareVault on Oct 10, 2016 9:00:00 AM



Jim McCarthy is a Business Development Expert helping Biopharma companies plan their partnership strategies and due diligence. He knows how to W.I.N.

Vault Series: Jim, when companies are doing due diligence, especially to strike a deal, how should they structure their documents for sharing? 

McCarthy: As a company, you need a roadmap to determine what you are willing to disclose at each stage in the game and to whom. 

Why? Because you might be submitting documents to several potential suitors who could become competitors one day. You never want to give away all the “competitive insights” too early. 

I recommend using a formula I coined long ago: W.I.N.: What’s Important Now? Know what "document sharing" stage you are in with your partners or suitors. It's like a game of chess. Most common stages are:

  1. ScreeningThese documents are your basic get-to-know-you information, generally non-confidential, that will engage stakeholders in the beginning and for preliminary determination of interest.

  2. Technical Data. Clinical data, regulatory filings, FDA information, IP, patents and other mission-critical information that “sets you apart” and makes you attractive for license or purchase. 

  3. Deal Making. Negotiation around when things get serious, everything is “on the table,” and you're ready to show your hand. (For great tips on how to prep for deal points, check out Linda Pullan's story from our Vault Series email 1)

Vault Series: What tools can biz dev executives use to prepare? And, as you know Jim, these kinds of tools just happen to be our specialty. 

McCarthy: Of course! None of this matters unless you have the data room structured to succeed. Here are my favorite tools that I recommend to my clients using ShareVault:

  • Granular Access Controls: Set permission and policy levels per user, including which documents they can access and how they can view/print them to prevent info getting into the wrong hands. 
  • Audit Trails: Be a detective and analyze how people are engaging with your information. These types of reports can help you shape your next round of sharing. It is useful for potential partners to know you are monitoring due diligence activity. Routinely, they are more discriminant in document reviews they request vs. ask for “everything.” This has “human productivity” implications to minimize unnecessary demands on your company and internal team.
  • Expiration Date: Need to move someone to the next level to W.I.N.? Place an expiration date on a document to encourage faster review and help keep all parties on a parallel time path. 

And if you have a panic in the middle of the night....there's this: 



About James A. McCarthy, CLP CorpDev Ventures - Corporate & Business Development, Alliance Management

Jim has 30 years of professional experience in life sciences. His background includes a 25 year career with Bristol-Myers Squibb and Eli Lilly & Company and over 15 years in international corporate business development and licensing roles. These efforts include projects and deals in over 30 countries, with over 80 completed agreements across a range of transactions. In recent years, he has been assisting small and emerging life science companies to leverage their IP assets with strategic and commercial planning, venture financing, commercial initiatives and deal support on a global basis.






Topics: Information

Visit Booth 111 at LES 2016 to Learn About Secure Document Sharing For Dealmaking

Posted by ShareVault on Oct 6, 2016 9:04:42 AM


LES 2016 Annual Meeting | October 23 – 26

Vancouver Convention Centre | Vancouver, BC

On October 23 – 26 Visit ShareVault - the 2016 Media Supporter - at Booth 111 at the LES 2016 Annual Meeting held in Vancouver, BC.

For more than 50 years, LES has been the leading association for intellectual property, technology and business development professionals to achieve professional and personal success. Whether you are new to licensing or an experienced licensing executive, the annual meeting is an invaluable resource. ShareVault will be there to meet with customers, partners and new acquaintance to discuss the benefits of a virtual data room and how technology can make licensing and partnering easier and more successful.

If you would like to set up a meeting with an on-site ShareVault team member, please email Steve Joseph


The Annual Meeting will include:

  • A prestigious list of over 105 speakers
  • 47 educational sessions
  • Over 1000 industry leaders representing more than 800 companies
  • Workshops
  • Receptions and networking opportunities

Join LES

The business of intellectual property and business is changing and new challenges are faced every day. A membership with the Licensing Executive Society (LES) can help you grow your network, hone your skills and knowledge, and advance your career. LES represents a highly diverse community of IP, business development and technology licensing professionals that collaborate across multiple industries to create a unique network and learning environment.

The LES Annual Meeting attracts an impressive list of attendees from companies in both the U.S. and Canada. To view the list click the button below.

Attendee List

About ShareVault

ShareVault® is the trusted document sharing solution (virtual data room) for licensing professionals sharing confidential intellectual property during due diligence. With unmatched enterprise grade security, functionality that simplifies document organization and viewing, and detailed analytics that track document activity, ShareVault gives organizations full access controls for document sharing. To learn more visit,

Topics: Company, Products, Events

Top Five Questions to ask before any Deal

Posted by ShareVault on Oct 3, 2016 9:00:00 AM



We sat down with partnership expert Linda Pullan, PhD, of Pullan Consulting, to get her insights on dealmaking in BioPharma.

Vault Series: Linda, for the last 10 years, you have been consulting biotech companies during the deal process. What do you find is the most common mistake made in deal preparation? 

Pullan: I see this one over and over. Companies don't ask themselves, "What do we want?" The necessity of thinking about desires and wishes ahead of time are undervalued. 

Vault Series: Why is this important? What can leaders do? 

Pullan: You need the whole team speaking and presenting the same language from the CEO to research. You need to know what you are willing to trade, because clear priorities lets the other side find a way they can give you what you want most.


1. What is the #1 purpose of doing a deal and what is essential or you won't do a deal? For example, bring a drug to market to help x. 

2. What can you give up to get your "must haves" and what is the priority order of your "nice to haves"? 

3. What are the alternatives to achieve if you don't do a deal? What are you doing to provide more alternatives (resulting in more bargaining power)? 

4. What has this potential partner done in past deals? 

5. What are industry common practices for these deals? For example, no indication splitting or deal averages by stage. 

For more on Linda Pullan, please visit her site or watch her in our Web Panel Discussion: The Nuts & Bolts of Due Diligence in Biopharma Partnering. You can also visit our BioPharma partnering series page for solution briefs and white papers. 



Stay tuned for our next Vault Series featuring another great BioPharma star with insights to make you a better deal maker.





Topics: News

Must-Know Finance Concepts For Life Sciences Valuations—Part 2 [Webinar]

Posted by Steve Joseph on Sep 28, 2016 9:00:00 AM

Must-Know-Finance-Concepts2-new.jpgShareVault is pleased to announce the presentation of a webinar on Thursday, October 13th at 11am—12pm PST / 2—3pm EST entitled "Must-Know Concepts for Life Sciences Valuations, Part 2." 

This webinar is a continuation of the first webinar, entitled "Must-Know Finance Concepts for Life Sciences Valuations," and goes into more detail on the key concepts and most common methodologies used to evaluate life sciences assets.

Questions answered in Part 2 include:

  • Which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions?

  • An explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital and present value

  • What are some cash flow examples for a situation when the asset is early in the product lifecycle, for out-licensed, and for in-licensed products?

  • How do my expected deal terms relate to my forecast cash flows? How can I use this to make better decisions on licensing timing?

And more. 

Register for Webinar

If you are an entrepreneur who plans to raise (or currently is raising) financing, licensing an asset or selling your company, a private investor who wants to estimate and negotiate start-up share value, or any other professional who is active in the life sciences investing sector, you'll benefit from this more detailed explanation of life sciences valuation methodologies.


JohnSelig.jpgJohn Selig, Co-Founder and Managing Partner, Mavericks Capital

John advises life sciences companies on M&A, licensing and financial strategy. John speaks frequently on topics in valuation, deal term benchmarking, and strategy. He teaches the Valuation and Finance module at BIO’s Executive Management Training course for BD professionals each year, as well as the Valuation module at Stanford Medical School’s Entrepreneurship Program.

Prior to joining Mavericks, John was a Managing Director at Woodside Capital Partners, a boutique investment bank. For the prior 12 years, he advised both Fortune 100 and VC-backed healthcare companies on transaction strategy and valuation at Strategic Decisions Group (SDG), a global management consulting firm, and Keelin Reeds Partners, a life sciences management consulting firm. While at Keelin Reeds, John led a partnership and M&A deal term benchmarking effort and has extensive experience in applying that data to yield market-value deal terms for dozens of assets, using the results to provide ongoing support during deal negotiations. Prior to consulting, John was an attorney with Weil, Gotshal and Manges LLP where he focused on M&A and corporate finance.

John holds a JD from Stanford Law School, where he was an Associate Editor of the Law Review, and a BA, magna cum laude, from Brown University, where he was a member of Phi Beta Kappa. (FINRA 24, 63, 79)

JeffKaran.jpgJeff Karan, Co-Founder and Managing Partner, Mavericks Capital

Jeff brings over 30 years of investment banking and corporate advisory experience to Mavericks Capital. He started his career in 1980 at Morgan Stanley and moved to Goldman Sachs six years later. In addition to his extensive knowledge of capital raising and merger & acquisitions, Jeff has advised clients on corporate strategy, business valuation, and a wide range of strategic partnership structures.

Mavericks Capital is the healthcare spinout of Woodside Capital Partners, a boutique investment bank Jeff founded in 2001. 

Jeff holds an MBA from Dartmouth’s Amos Tuck School of Business Administration (Tuck Scholar), a BA in Economics from Dartmouth College, and later received an MA on the west coast in Comparative Philosophy and Religion. Jeff is an avid skier and cyclist and is passionate about philosophy, the history of ideas, poker theory, and global economic analysis. (FINRA 7, 24, 63, 79, 99)

If you missed Part 1 of the series, you can download the white paper derived from it here:

Download the White Paper



Topics: Webinars

Putting on the Pitch—How to Present to VCs and In-Licensors [Live Streaming Video]

Posted by Steve Joseph on Sep 27, 2016 10:55:15 AM

BIO_Header.pngPlease join us for:


Thursday, September 29th, 2016 | 1pm ET / 10am PT

The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One PartneringTM meetings. The forum takes place in San Fransisco on October 18-19. You can register here.

To best prepare for for the partnering process consider attending a live streaming video event on September 29th where top VCs and Business Development Executives will give you valuable tips on how to perfect your pitch. 

RSVP for the web panel to ask your question in advance or ask them during the live panel.


  • Rajeev Dadoo, Partner, SR One
  • Karl Handelsman, Founder, Codon Capital
  • Ed Hurwitz, Managing Director, Precision, BioVentures
  • Alex Szidon, Executive Director, BD&L, Head, W. Coast Inno Hub, Merck & Co.
  • Sougato Das, Managing Director, Partnering, BIO (moderator)


  • How to put together the optimal pitch deck
  • What to say and do in a partnering meeting
  • What to say and do in a company presentation
  • How to write a good meeting request, and other partnering tips
  • How to follow up after a good meeting
  • How to handle confidential information
  • Common mistakes, and much more


Ryan_Watts.jpgJust Announced: Ryan Watts, PhD, Chief Executive Officer, Denali Therapeutics Inc. to speak at the BIO Investor Forum



To take advantage of the special BIO Investor Forum room rate at the Westin St. Francis Hotel, be sure to book your reservation today.

You can also further prepare for the forum by downloading ShareVault's series of White Papers and Webinars focused on BioPharma partnering.

ShareVault's Bio Partnering Series of White Papers & Webinars

Topics: Events

ShareVault Announces eCTD Viewer – Major Advancement Tailored for Biopharma Regulatory Submissions

Posted by John Badger on Sep 19, 2016 2:10:55 PM

ShareVault Is the first dataroom to allow viewing documents within an eCTD Viewer

Today, ShareVault is announcing its eCTD Viewer at the 2016 RAPS Regualatory Convergence in San Jose, CA (#2016RAPS, booth 527). ShareVault is the first data room provider to offer integration with an eCTD viewer.  The innovative new capability allows for efficient review of biopharma regulatory submissions, such as INDs (Investigational New Drug Applications) and NDAs (New Drug Applications), in the eCTD (electronic Common Technical Document) format.  The viewer, developed jointly with DoubleBridge Technologies, Inc., is based on the industry-leading ROSETTA Phoenix™ eCTD Viewer, and is seamlessly integrated within the ShareVault data room.

When biopharma companies share submissions with third parties, the documents typically have to be shared in unprotected format in order to be viewed in an eCTD viewer.  The problem is that then the company has lost control of highly sensitive, confidential information within the submission.  Typically, sensitive information is shared with third parties using one of the leading virtual data room providers, which allows for full control and monitoriing of the disclosed information, including the ability to "remotely shred" disclosed documents, and track user viewing activity down to the page level.  The problem is that until now, eCTD submissions shared in a virtual data room do not preserve the structured presentation and inter-document hyperlinks offered by an eCTD viewer, making it much more tedious for third parties to review regulatory submission documents.  The new integrated viewer allows for protected sharing of regulatory submissions.

"We are thrilled to be the first data room provider to offer integration with an eCTD Viewer, and we couldn't be happier with how tightly we have been able to integrate with ROSETTA Phoenix, giving our users a simple, efficient and extremely secure solution for sharing regulatory submission documents.", said John Badger, ShareVault's co-founder and VP of Marketing and Product.

To sign up for a demo of the new ShareVault eCTD Viewer,  click the button below:

  Schedule a Demo


Topics: Products, Life Sciences

Biopharma Dealmakers – What is an eCTD, and Why Should You Care?

Posted by John Badger on Jul 13, 2016 4:28:19 PM

Experienced biopharma dealmakers know that pharma companies seeking to partner with a biotech will require full disclosure of the regulatory submission documents. During due diligence, they will need to share the entirety of the IND or NDA with a potential partner. While many business development professionals may regard the internals of the IND or NDA as a huge black box of documents, regulatory professionals know this structure of documents inside the electronic submission is called an eCTD (electronic Common Technical Document).eCTD.png

The eCTD format is a complex nested hierarchy, which is not easy to read. For this reason,  several software companies have developed eCTD viewers, which make reviewing regulatory documents faster and more convenient, and which enable more efficient identification of the critical information contained in the submission.

Why Should Dealmakers Care?

We all want due diligence to go as quickly as possible, since less time generally translates into better deal terms. Experienced dealmakers know that if due diligence doesn't go swiftly, it can result in unfavorable changes in business conditions or the loss of deal momentum. They also know that most of the documents in a biopharma partnering due diligence data room are regulatory documents, and that most of the time spent in due diligence document review is related to reviewing those documents.

Regulatory experts on the due diligence team would love to request the full eCTD submission, which they could then load into an eCTD viewer in order to accelerate due diligence. But they know that you would never want to give them the full submission because once you've shared it in eCTD format, you can't "unshare" it if the deal goes south. So without an eCTD viewer, the due diligence teams instead slog through the eCTD submission in the dataroom's built-in viewer.

ShareVault is very excited to announce the release in a few weeks of a new integrated eCTD viewer, developed in collaboration with one of the leading providers of eCTD viewing software for pharmaceutical companies and biotech companies alike.  

First Data Room With an Integrated eCTD Viewer

ShareVault has always been the innovation leader in data rooms. One example is our support of document-to-document hyperlinking, which is another vital way to accelerate the review of regulatory submission documents. ShareVault has been–and still is–the only data room to support this essential feature.

One important capability offered by ShareVault's integration with the eCTD viewer is that the ShareVault administrator can decide which sections of the eCTD (pre-clinical, clinical, quality, manufacturing, etc.) should be permissioned to the different parties involved.  This gives our customers fully granular control of the permissions within the submission itself.

The new secure eCTD viewer will significantly accelerate the speed of regulatory due diligence. The announcement will reinforce our commitment to the life sciences industry as the only data room that has features specifically developed for life sciences.

Stay tuned for the official announcement of the collaboration. We have already started beta testing and will be going live this summer with this exciting new feature.

Topics: Products, Life Sciences, Due Diligence

White Paper Now Available! Must-Know Finance Concepts for Life Sciences Valuations

Posted by ShareVault on Jul 1, 2016 12:18:07 PM

WP-MustKnow-Finance-Concepts-1-sm-2.jpegOn March 3rd ShareVault presented a free webinar titled "Must-Know Finance Concepts for Life Sciences Valuations." That webinar has now been translated into a white paper and is available for dowload here:

Get the White Paper

This white paper presents an introduction to the key concepts and most common methodologies used to evaluate life sciences assets. 

If you are an entrepreneur who is, or will be, raising financing, licensing an asset or selling your company, a private investor who wants to estimate and negotiate start-up share value, or any other professional who is active in the investing sector, you'll benefit from this overview of the key concepts used in life sciences valuation discussions.

Topics covered include: 

  • The various valuation methodologies used to assign a value to life science businesses and assets 

  • The methodologies used in particular by pharma partners and venture capitalists 

  • An explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital and present value

JohnSelig.jpgAbout the Authors:

John Selig, Co-Founder and Managing Partner, Mavericks Capital

John advises life sciences companies on M&A, licensing and financial strategy. John speaks frequently on topics in valuation, deal term benchmarking, and strategy. He teaches the Valuation and Finance module at BIO’s Executive Management Training course for BD professionals each year, and he will be teaching the Valuation module at Stanford Medical School’s Entrepreneurship Program.

JeffKaran.jpgJeff Karan, Co-Founder and Managing Partner, Mavericks Capital

Jeff brings over 30 years of investment banking and corporate advisory experience to Mavericks Capital. He started his career in 1980 at Morgan Stanley and moved to Goldman Sachs six years later. In addition to his extensive knowledge of capital raising and merger & acquisitions, Jeff has advised clients on corporate strategy, business valuation, and a wide range of strategic partnership structures.

About Mavericks Capital:

Mavericks Capital and its licensed broker dealer, Mavericks Capital Securities, specializes in M&A, capital raises and strategic partnerships across the healthcare sector. They help construct and facilitate innovative and lucrative solutions for their clients. Their practices include therapeutics, devices, diagnostics, services and digital health. For more information, visit

Get the White Paper

Topics: White Papers

Get Your Free BioPharma Partnering Poster

Posted by Steve Joseph on Jun 21, 2016 9:16:49 AM

year_in_review_infographic-1.pngIt was great to be at BIO in San Francisco this year and see so many of our friends. If you didn't have a chance to take home our poster showing the partnering deals done by the top global pharma companies with biotech companies, grouped by therapeutic area, you can get one here.

The Official Data Room for BIO
ShareVault is proud to have been selected as the official data room provider for BIO and more than 30 other life sciences industry associations. We were selected because ShareVault is the only data room that provides features specifically developed to accelerate BioPharma partnering due diligence.

Much Faster Review of Regulatory Documents
Our exclusive document-to-document hyperlinking allows faster review of regulatory documents in your IND, NDA and subsequent resubmissions.

Fastest Data Room
ShareVault is a responsive, low-latency web application, making it the fastest data room on the market. ShareVault is quick to configure and set up, with fast drag-and-drop uploading, easy-to-organize tagging and batch operations that make it a snap to manage users and configure permissioning. It’s also faster for your end users, with high speed scrolling, instant fulltext search and a plug-in free document viewer that works in any browser.

Used by 44 of the 45 Top Global Pharma Companies
Big Pharma is already familiar with using ShareVault for BioPharma due diligence, which means that you can rest assured that your due diligence process will be streamlined – a good data room should speed up due diligence, not get in the way.


Free Resources for BioPharma Dealmakers
Did you know that ShareVault, in addition to being the best data room provider to the BioPharma industry, has free resources for BioPharma dealmakers? Here are just a few of our white papers targeted to BioPharma partnering:

WP-MustKnow-Finance-Concepts-1-sm-2.jpegMust-Know Finance Concepts for Life Sciences Valuations

This white paper, based on the webinar by the same name, presents an introduction to the key concepts and most common methodologies used to evaluate life sciences assets. 

If you are an entrepreneur who is, or will be, raising financing, licensing an asset or selling your company, a private investor who wants to estimate and negotiate start-up share value, or any other professional who is active in the investing sector, you'll benefit from this overview of the key concepts used in life sciences valuation discussions.

Authors: Jeff Karan and John Selig, Mavericks Capital

                                                   Get the White Paper


What's Hot & What's Not in Immuno-Oncology LicensingWP-Immuno-Oncology-BIO-sm.jpg

If you are developing an immuno-oncology drug or working toward in- or out-licensing of an immuno-oncology drug, you will want to read these perspectives.


  • Linda Pullan, PhD | Pullan Consulting
  • Jeff Bockman, PhD | Defined Health
  • Ferran Prat, PhD | MD Anderson
  • Axel Hoos, MD, PhD | GlaxoSmithKline Pharmaceuticals (GSK)
  • Nate Sanburn, MS | Eli Lilly & Company (Lilly)

Get the White Paper


Four Essential Steps to Successful BioPharma PartneringFour_Essential_Steps_wp_thumb.gif

Successful BioPharma partnerships don't happen by accident. And negotiating an out-licensing deal can be a daunting task – especially since the company may also be progressing the clinical portfolio.

This white paper, based on the webinar by the same name, provides you perspectives on the major steps required for a successful transaction.

Gautam Aggarwal, a partner with Triangle Insights Group, walks you through the essential steps that will maximize your chance of partnering success.

Get the White Paper


WP-SuccessfulLicensingNeg-BIO-sm.jpgSuccessful Biotech Licensing Negotiations

Biotech companies seeking to partner their drug candidates should decide in advance what they want to achieve in deal negotiations. Getting the best outcome depends on non-financial, as well as financial terms. In this white paper, Linda Pullan provides licensing negotiations insights from a biotech business development perspective.


Linda M. Pullan, Ph.D. | Pullan Consulting

Get the White Paper



Topics: Information, White Papers

ShareVault and IRIS Announce Strategic Alliance to Provide End-to-End Product Management Solution for Life Sciences

Posted by Richard Andersen on Jun 6, 2016 10:16:00 AM

iris-interactive_logo-1.jpgLos Gatos, CAShareVault, an industry-leading provider of life science virtual data rooms, along with IRIS Interactive, a leading provider of proven software which enables life science companies to streamline the drug development process, announced today that they have formed a strategic alliance in order to provide an End-to-End Product Management Solution for the Life Sciences Industry across biotechnology, large pharma, and medical device companies.

Together the two companies provide an end-to-end platform for life science product lifecycle management—from discovery to partnering to commercialization—that is collaborative, secure and customizable when setting permissions for third parties to view sensitive documents. The combined solution is appropriate for life science companies of all sizes and stages of development.

IRIS Interactive helps life sciences companies accelerate time to market and achieve greater success rates with both new product development and new product launches. ShareVault facilitates the sharing of sensitive documents with third parties during transaction due diligence, partnering and other critical business processes. The end-to-end solution combines the companies’ strengths to deliver customers with a significant edge in bringing products to market.
While working for a leading pharmaceutical company, IRIS Interactive Chief Executive Janaki Joshi observed that the finance function relied on accounting systems to track day-to-day operations and for reporting to the board. However, the teams involved in product development, commercialization and brand management did not have a central tracking and document system to manage their product pipeline and brands, or to demonstrate the value they were delivering to the board and others in the company. Joshi therefore founded IRIS Interactive with the vision to provide a central product development, commercialization and marketing platform designed and customized to manage the key day-to-day operations of the company’s pipeline and brands, while at the same time retaining all the knowledge and learning from the process, as well as reporting the value delivered to the business.

drug_costs_image.jpg“Knowledge gathered during the drug development process does not get shared effectively,” stated Joshi. “And every week of delay costs millions of dollars. What’s needed is a centralized platform to manage information so all teams can operate more efficiently, collaborate in real time, benchmark, monitor how long processes take, identify sources of delay and quickly fix them. That’s what IRIS provides.”

ShareVault was established in 2003 as an on-demand, cloud-based web platform that provides an organized document repository with bank-grade security for sharing confidential documents with third parties. ShareVault has facilitated hundreds of billions of dollars in business transactions, has customers in 48 countries, and is routinely used for sharing confidential documents during the drug development process and for bio-pharmaceutical partnering collaboration.

“The value of a life sciences asset is embodied in its information,” stated Richard Andersen, Chief Executive Officer of ShareVault. “Ensuring that the information about an asset is comprehensive, complete, current, organized and secure, as well as accessible to the parties that must have access to that information — and not accessible to those who don’t — is critical for maximizing the value of the asset. We are very excited about the alliance between IRIS and ShareVault because it will further facilitate the active collaboration among internal and external stakeholders during life science asset development and commercialization.”

IRIS Interactive has been in operation for over 12 years and has offices in the USA, Australia and India. Their platform is currently being used by over 10,000 healthcare staff members in 25 countries.

CONTACT: Julie May | Team May Day |

CONTACT: Rachel Pharn | Product Consulting Associate | IRIS Interactive |

Topics: News

New Module

Add content here.

About ShareVault

Simple & Secure Document Sharing

ShareVault offers virtual data rooms for securely sharing documents with third parties. Typically used to share due diligence documents during M&A, partnering, fundraising and other dealmaking scenarios, ShareVault is increasingly being used for a wide variety of other applications, primarily in highly regulated industries, for securely sharing documents with third parties. ShareVault can be set up and deployed in an hour, yet offers enterprise-grade security and scaleability.

Learn More Share Documents. Simply, Securely.

Subscribe to Email Updates